ArticleAnnals of clinical microbiology and antimicrobials2025
Bactericidal activity and Inhibition of levofloxacin-induced resistance by antibacterial combination against hypervirulent Klebsiella pneumoniae.
Article in Annals of clinical microbiology and antimicrobials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHypervirulent Klebsiella pneumoniae (hvKP) infection is characterized by its potential severity and metastatic propensity, underlying the importance to employ bactericidal treatment promptly for infection source control. The aim of this study is to investigate the bactericidal activity of antibacterial combination against hvKP, with a particular focus on whether levofloxacin-based combinations can suppress levofloxacin-induced efflux pump related drug resistance.
methodsWe conducted in vitro antimicrobial susceptibility tests on 12 hvKP clinical isolates and the reference strain NTUH-K2044. Checkerboard assays were conducted to evaluate the combination activity of levofloxacin with amikacin or ceftazidime. Time-kill experiments were performed to determining the bactericidal activities of levofloxacin, amikacin, ceftazidime, and the levofloxacin-based combinations against NTUH-K2044. Additionally, the mechanisms underlying induced quinolone resistance were investigated.
resultsTwelve clinical hvKP isolates were highly susceptible to levofloxacin, amikacin, and ceftazidime. The levofloxacin-amikacin and levofloxacin-ceftazidime combinations both demonstrated antibacterial activities as indifference. Time-kill experiments showed that an eight-fold or lower minimal inhibitory concentration (≤ 8×MIC) of levofloxacin, ≤ 1×MIC of amikacin and of ceftazidime, exhibited bactericidal activity against NTUH-K2044 during the initial 1-4 h with various levels of bacterial counts decreasing followed by regrowth. The regrowth samples had high levofloxacin MICs indicating the occurrence of induced resistance. Real-time PCR and wild-type oqxR complementation demonstrated point mutations in oqxR of NTUH-K2044, resulting in an overexpression of the efflux pump encoding gene of oqxAB. Both the levofloxacin-amikacin and levofloxacin-ceftazidime combinations exhibited bactericidal synergy without bacterial regrowth when they were tested with 2×MIC of levofloxacin combined with either 1/2×MIC of amikacin or 1×MIC of ceftazidime.
conclusionsThese results demonstrated that levofloxacin combined with amikacin or ceftazidime exhibited superior bactericidal activities compared to levofloxacin against hvKP and might prevent levofloxacin-induced resistance related to oqxAB overexpression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.